BLUE JET HEALTHCARE LTD
Latest filings
- Routine compliance certificate filed with exchanges for Jul-Sep 2026 · Compliance
- Trading Window Closure for Insiders Ahead of Q2 Results · Compliance
- AGM results: all 6 resolutions passed, Re.1.20 dividend declared · Board & Shareholder Meetings
Snapshot
What the business is, and whether it's a good one at a fair price.
Manufactures specialty chemicals and pharmaceutical intermediates for global pharmaceutical customers across three verticals. The contrast media vertical supplies gadolinium and iodinated contrast media intermediates to formulation customers; FY26 revenue grew 23% YoY on new product launches, with Q4 alone surging 91% YoY to INR 193 crore. PI/API revenue fell 35% YoY to INR 298 crore as customers worked through inventory, but management says destocking is complete and FY27 should exceed the FY25 peak of ~INR 460 crore. A third vertical in high-intensity sweeteners is under validation, with trial shipments expected over coming quarters. Manufacturing runs from Ambernath and Mahad; Mahad Unit 3 backward integration for a contrast media raw material begins production in H2 FY27 to improve margins via supply chain self-reliance. New capacity at Vizag (a multi-year greenfield project) and a peptide-focused R&D centre in Hyderabad are being added; raw materials account for 41% of revenue and the company closed FY26 debt-free with INR 400 crore in liquid assets.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Concerns
Charts
How has the market priced it — with filings on the timeline?
BLUEJET · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from BLUE JET HEALTHCARE LTD's filed financials and exchange disclosures
What does BLUE JET HEALTHCARE LTD do?
BLUE JET HEALTHCARE LTD is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol BLUEJET.
Is BLUE JET HEALTHCARE LTD profitable?
Yes. Over the trailing twelve months BLUE JET HEALTHCARE LTD reported a net profit of ₹235 Cr on revenue of ₹886 Cr.
Does BLUE JET HEALTHCARE LTD pay a dividend?
Yes. The dividend yield is 0.24% at the current price. It paid out 8% of its profit as dividend in FY26.
Is BLUE JET HEALTHCARE LTD debt-free?
Yes. It reported no borrowings on its 31 Mar 2026 balance sheet, and ₹61 Cr of cash.
Is BLUE JET HEALTHCARE LTD expensive compared with its peers?
On trailing P/E, BLUE JET HEALTHCARE LTD ranks 97 of 158 in Pharmaceuticals — cheaper than 39% of them, against an industry median of 30.1×. This is a position, not a valuation judgement.
How much does the BLUE JET HEALTHCARE LTD share price move in a day?
On a typical session BLUE JET HEALTHCARE LTD moves 1.49% — that is the median absolute close-to-close move across its last 267 trading days. MarketPing measures each filing's price reaction against it.
Where can I track BLUE JET HEALTHCARE LTD's announcements?
Every NSE and BSE filing by BLUE JET HEALTHCARE LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.